(R)-Pirtobrutinib

• CAT Number: I045465
• CAS Number: 2101700-14-3
• Molecular Formula: C22H21F4N5O3
• Molecular Weight: 479.43
• Purity: ≥95%
• Synonyms: 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2R)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
• InChI: InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m1/s1
• InChIKey: FWZAWAUZXYCBKZ-LLVKDONJSA-N
• SMILES: CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N

(R)-Pirtobrutinib (Cat No.: I045465) is the R-enantiomer of pirtobrutinib, a highly selective, reversible inhibitor of Bruton’s tyrosine kinase (BTK), a key enzyme in B-cell receptor (BCR) signaling that regulates B-cell activation, proliferation, and survival. Unlike covalent BTK inhibitors, it targets both wild-type and C481-mutated BTK, overcoming resistance seen in some patients. (R)-Pirtobrutinib is investigated for treating B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is also used as a research tool for studying BTK-mediated immune and oncogenic pathways.

Reference

[1]. Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644.